Showing 6401-6410 of 18633 results for "".
Food Allergies and Atopic Dermatitis in the Pediatric Population
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/food-allergies-and-atopic-dermatitis-in-the-pediatric-population/37175/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses potential links between food allergies and pediatric atopic dermatitis, and how to address them.Defining the Challenge in Complex Cases of Psoriatic Arthritis
https://reachmd.com/programs/living-rheum/complex-psoriatic-arthritis-cases/54445/Managing psoriatic arthritis gets more complex when patients don’t respond to standard treatments or present with overlapping conditions. Hear Dr. Laura Coates' insights on difficult-to-treat and complex-to-manage psoriatic arthritis—highlighting how clear classification can guide more targeted therDecoding the Data: Early Biologic Use and Psoriatic Arthritis
https://reachmd.com/programs/living-rheum/early-biologic-use-psoriatic-arthritis/51051/Can treating psoriasis early with biologics help prevent psoriatic arthritis? The data’s promising—but it’s complicated. Join Dr. Laura Coates as she unpacks the latest research, explaining how early intervention may influence outcomes and what real-world challenges come with interpreting observatioEnsuring Equity for Your Patients
https://practicaldermatology.com/series/the-practical-dermatology-podcast/ensuring-equity-for-your-patients/54335/Jeanine Downie, MD, FAAD, and an expert panel discuss implicit bias and discrimination against various marginalized populations and how to be proactive in avoiding these problems in your practice. Joining Dr. Downie are Drs. Mona Gohara, Anthony Rossi, Jacob Beer, and Jane Yoo. This discussion is baRedefining ATTR Treatment: Key Mechanisms and Emerging Data
https://reachmd.com/programs/heart-matters/attr-treatment-mechanisms-emerging-data/49057/New therapeutic approaches are reshaping how we think about managing transthyretin amyloidosis (ATTR). Gain insight into the next generation of ATTR therapies as Dr. Ahmad Masri highlights evolving strategies beyond traditional stabilizers. He's an Associate Professor of Medicine in the Division ofAdvancing HER2-Targeted Therapy in GI Cancers
https://reachmd.com/programs/project-oncology/her2-targeted-therapy-gi-cancer/49170/The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomeAdvances in ATTR-CM: Evolving Diagnostics and Therapeutics
https://reachmd.com/programs/clinicians-roundtable/advances-attr-cm-diagnostics-therapeutics/49055/In the past decade, significant strides have been made in diagnosing and treating patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Increased disease awareness, non-invasive diagnostic tools like scintigraphy, and AI-assisted screening have led to earlier detection and improved outcomes.Continuing the Dry Eye Conversation
https://reachmd.com/podcasts/to-the-point/continuing-the-dry-eye-conversation/54334/Kicking off the first episode of the To the Point podcast in 2026, co-hosts Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, FAAO, continue the dry eye conversation with DED pearls to implement in clinic. They cover everything from patient signs, symptoms, and side effects to in-office tools, treatHow AI Is Transforming Biomarker Development in GI Oncology
https://reachmd.com/programs/clinicians-roundtable/ai-biomarker-development-gi-oncology/49169/From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains how AI is being applied to data to identify tumor features and treatment susceptibilities faster and moreBeyond Symptom Control: Optimizing Functional Outcomes in Schizophrenia Care
https://reachmd.com/programs/neurofrontiers/beyond-symptom-control-optimizing-functional-outcomes-in-schizophrenia-care/36646/Functional recovery—not just symptom reduction—is becoming the new standard in schizophrenia care. Given this shift, psychiatric nurse practitioner Ashley Baker speaks with Dr. Stephen Marder about how integrated treatment models combining pharmacologic and psychosocial interventions can improve fun